Cancer Research, Statistics, and Treatment/Volume 5/Issue 3/July-September 2022 more
heavily pre‑treated, with a lesser number of patients with tobacco use (63.4 vs. 80%), more …

Cancer Research, Statistics, and Treatment/Volume 5/Issue 4/October-December 2022 to
those reported in the standard treatment arms (single agent therapies) of KN‑040 and CM …

Background: Head-and-neck squamous cell carcinoma (HNSCC) is one of the most
aggressive malignant tumors and is commonly diagnosed at an advanced stage. In the …

Background: Head-and-neck squamous cell cancers (HNSCC) are common in India.
Recurrent and metastatic HNSCC carry a poor prognosis. The chemotherapy options are …

Pantoprazole decreases the acidity of the tumor microenvironment by inhibiting proton
pumps on the cancer cell. This possibly leads to increased sensitivity to cytotoxic therapy …

ObjectiveTo evaluate the rates and patterns of distant metastasis in head and neck SCC at
the time of presentation and to study the association between distant metastasis with pre …

Head-and-neck cancer is one of the most common cancers in low-and middle-income
countries.[1] It leads to a significant burden in terms of cancer-related mortality and morbidity …

Dr. Patil and colleagues are to be congratulated for their retrospective real-world study,
titled,''Bendamustine in the third line or beyond in metastatic, recurrent, or relapsed head …

Background: Patients with platinum-refractory disease who experience early treatment
failure of head and neck squamous cell carcinoma (HNSCC) exhibit a dismal prognosis …

3. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for
recurrent squamouscell carcinoma of the head and neck. N Engl J Med 2016; 375: 185667 …